Top Markets
Coin of the day
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
Rang in Aktien #18445
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Aktienkurs
$0.27824149
Marktkapitalisierung
$198.06M
Veränderung (1 Tag)
-1.24%
Veränderung (1 Jahr)
-11.01%
Land
TW
Handel TaiGen Biopharmaceuticals Holdings Limited (4157)

Kategorie

Kursverlauf für TaiGen Biopharmaceuticals Holdings Limited (4157)
Höchster Schlusskurs: $0.28 am 2026-09-01

Niedrigster Schlusskurs: $1.49 am 2013-08-01
Kursverlauf der Aktie von TaiGen Biopharmaceuticals Holdings Limited von 2013 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -13.76%
2025 8.10%
2024 -28.68%
2023 -6.08%
2022 -5.50%
2021 -30.39%
2020 28.90%
2019 10.79%
2018 -22.39%
2017 -18.30%
2016 -14.71%
2015 -14.32%
2014 -40.68%
2013 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$556.43 40.29%
US
$1.05K 45.39%
NL
$152.82 535.43%
US
$123.10 -8.92%
AU
$757.71 6.76%
CH